Skip to content

Burning Rock Biotech Ltd

BNR· NasdaqCore metricsCIK 1792267

Medical laboratories28 peers

Last sale
Nov 12, 2026 · +3.66%
Market cap
$150.99M
10.89M shares
Filings
170
$77.16M
FY 2025+9.2% FY25 yoy
-$7.92M
FY 2025N/M FY25 yoy
-$7.84M
FY 2025N/M FY25 yoy
-$4.82M
FY 2025derivedN/M FY25 yoy
$0.00
FY 2021
$68.41M
FY 2025−3.9% FY25 yoy
$150.99M
—
2.0×
2.0×
-3.19%
—

FY2025 figures · derived

Price

$13.87+13.60%+$1.66past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$77.16MFY 2025
$81.66M0FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$77,157,000reported
FY 20242024-12-31$70,667,000reported
FY 20232023-12-31$75,696,000reported
FY 20222022-12-31$81,662,000reported
FY 20212021-12-31$79,694,000reported
FY 20202020-12-31$65,885,000reported

Capital returns

Dividends and buybacks · FY2020 to FY2021
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2021—$0.00$0.00————
FY2020—$0.00$0.00—0.00 sh−100.0%—

Segments

Revenue by Segments, FY2018 to FY2025FY2018In-hospital business · FY2018 · CN¥33.19MCentral laboratory business · FY2018 · CN¥161.46MPharma research and development services · FY2018 · CN¥14.22MFY2019In-hospital business · FY2019 · CN¥87.68MCentral laboratory business · FY2019 · CN¥276.25MPharma research and development services · FY2019 · CN¥17.75MFY2020In-hospital business · FY2020 · CN¥117.87MCentral laboratory business · FY2020 · CN¥297.34MPharma research and development services · FY2020 · CN¥14.69MFY2021In-hospital business · FY2021 · CN¥165.12MCentral laboratory business · FY2021 · CN¥319.35MPharma research and development services · FY2021 · CN¥23.39MFY2022In-hospital business · FY2022 · CN¥175.30MCentral laboratory business · FY2022 · CN¥314.77MPharma research and development services · FY2022 · CN¥73.17MFY2023In-hospital business · FY2023 · CN¥188.70MCentral laboratory business · FY2023 · CN¥232.81MPharma research and development services · FY2023 · CN¥115.92MFY2024In-hospital business · FY2024 · CN¥224.49MCentral laboratory business · FY2024 · CN¥175.65MPharma research and development services · FY2024 · CN¥115.68MFY2025In-hospital business · FY2025 · CN¥224.04MCentral laboratory business · FY2025 · CN¥159.99MPharma research and development services · FY2025 · CN¥155.54M
LineFY2025ShareChange
In-hospital businessCN¥224.04M42%−0.2%
Central laboratory businessCN¥159.99M30%−8.9%
Pharma research and development servicesCN¥155.54M29%+34.5%
TotalCN¥539.57M

From the 20-F filed Apr 28, 2026BNR

Medical laboratories

Burning Rock Biotech Ltd is the 16th largest of the 29 covered companies the SEC files under this code, by revenue. SIC 8071

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Burning Rock Biotech Ltd · CIK 1792267 · Engraved from SEC EDGAR